Physician profile
Won Im
NPI 1508932989
$18,240.77
in general payments reported to CMS, 2019-2025
25 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,806 · 2020: $1,584 · 2021: $2,667 · 2022: $2,445 · 2023: $3,482 · 2024: $3,037 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,712 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,711.65 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,546.59 | 2021-2025 | |
| Alkermes, INC. | $2,110.53 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,091.54 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,616.71 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $1,534.31 | 2019-2022 | |
| Lundbeck LLC | $1,517.95 | 2019-2025 | Rexulti, Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $1,139.52 | 2019-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $947.94 | 2020-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $900.12 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $678.60 | 2022-2024 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $664.08 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Allergan, INC. | $583.21 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $457.37 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $385.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $328.12 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $231.74 | 2021-2023 | Qelbree |
| Corium, LLC | $189.87 | 2022-2024 | Azstarys |
| Eisai INC. | $88.54 | 2021 | |
| Idorsia Pharmaceuticals US INC | $66.67 | 2023 | Quviviq |
| Shire North American Group INC | $42.30 | 2019 | |
| Alfasigma USA, INC. | $42.19 | 2021 | |
| Bausch Health US, LLC | $21.31 | 2020 | |
| Noven Therapeutics, LLC | $21.00 | 2021 | |
| Noven Pharmaceuticals, INC. | $20.70 | 2021 | |
| Adlon Therapeutics L.P. | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Won Im listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.